I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESCMID 2024

-
Coming soon
10:00 AM
Duration 90mins Barcelona, Spain
Real-world evidence comparing the risk of Delta and Omicron infection outcomes by SARS-CoV-2 antibody levels
Jin Y, Yang F, Rank C, Letovsky S, Ramge P, Jochum S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Influenza A and B viral loads are higher in nasopharyngeal swabs compared to mid-turbinate swabs
Wildum S, Katugampola L, Bernasconi C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:45 PM
Duration 12mins Hall C
Optimized arylomycins GDC-5780 and GDC-0829 represent a promising novel class of antibiotics against gram-negative pathogens
Koehler et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:00 AM
Duration 90mins Barcelona, Spain
Pharmacokinetics and safety in ICU patients and healthy participants following single dose administration of zosurabalpin (RG6006), a novel pathogen- specific antibiotic for the treatment of serious Acinetobacter infections
Cottreel et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Preliminary zosurabalpin broth microdilution quality control ranges using clinical and laboratory standards institute M23 criteria
Huband et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Assessment of zosurabalpin activity in combination with other antibiotics
Sabatini et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
MIC distributions and activity of the novel anti-Acinetobacter agent zosurabalpin (RG6006)
Hawser et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Mechanism of in vitro resistance to zosurabalpin (RG6006) in Acinetobacter baumannii
Trauner et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Target identification and mode of action studies of zosurabalpin (RG6006)
Pahil et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Determination of the PK/PD driver for the LepB inhibitor, GDC-0829, a novel broad-spectrum antibiotic against gram-negative bacterial infections
Xu et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Determination of the PK/PD driver for the LepB inhibitor, GDC-5780, a novel Gram-negative antibiotic against Enterobacteriaceae infections
Xu et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Low frequency of spontaneous resistance to LepB inhibitors, GDC-5780 and GDC-0829, in target gram-negative bacterial species
Girgis et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
In vitro killing kinetics of GDC-5780, a novel gram-negative antibiotic, against a panel of Enterobacteriaceae isolates
Dieppois et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Developing the arylomycins into novel antibiotics against Gram-negative bacteria
Koehler et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:42 PM
Duration 6mins Barcelona, Spain
In vitro activity of two novel antibiotics, GDC-5780 and GDC-0829 against a global panel of gram-negative priority pathogens
Dieppois et al.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar